Company intelligence / Profile preview

Naveris

Waltham, Massachusetts, USAnaveris.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

NavDx detects HPV-associated head and neck and anal cancers with high sensitivity and specificity for earlier recurrence and molecular residual disease surveillance, with published studies showing positive predictive value (PPV) of 98% and negative predictive value (NPV) of 95% for anal cancer MRD[4][5][1]. Clinical results include detection of recurrence in 91% of head & neck cancer patients ahead of imaging, with a median lead-time of 3.9 months[5].

Therapeutic areas: Oncology
Modalities: Diagnostic (liquid biopsy)Digital droplet PCR (technology for DNA detection)
Industry: Molecular Diagnostics

Drug pipeline

1 asset

NavDx

Commercial

Indications: HPV-related cancer

Partnerships

Commercial payor coverage partnership (e.g., Blue Shield of California for NavDx test)

Beyond the preview

Go deeper on Naveris.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naveris.

Explore the full profile